Similarly, a proof-of-concept clinical trial enrolling 50 patients with advanced HCC after sorafenib failure reported that additional RFA or MWA to anti-PD-1 therapy (nivolumab or pembrolizumab) increased the response rate from 10% to 24%. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.